MNPR SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2026

10-K/A

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Apr 1, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 27, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Monopar Therapeutics Reports Q2 2026 Financial Results and Progress on ALXN1840 NDA Submission

Aug 12, 2026

8-K

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

Jul 22, 2026

8-K

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

Jun 30, 2026

8-K

Monopar Presents New Phase 3 FoCus Data Showing ALXN1840 Provides Superior Neurologic and Clinical Benefit in Wilson Disease

Jun 26, 2026

8-K

Monopar Therapeutics Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 23, 2026

8-K

Monopar Therapeutics Presents Phase 2 Results for ALXN1840 in Wilson Disease

May 29, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Sep 24, 2025

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Jan 27, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Dec 23, 2024

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Dec 18, 2024

424B5

Oct 29, 2024

424B5

PENDING OFFERING | Float: 2,193,302 | Amount sold to date: $4,675,426.00 | Bank: Rodman & Renshaw LLC

Oct 28, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8 POS

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Jul 22, 2026

S-8 POS

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Jul 22, 2026

S-8 POS

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Jul 22, 2026

S-8 POS

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Jul 22, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 22, 2026

S-3

August 2025 SHELF | Offering amount: $300,000,000

Aug 29, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 23, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jul 22, 2024

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Jul 11, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Anderson Raymond (Reporting)

Nov 4, 2026

Tsuchimoto Kim R (Reporting)

Nov 4, 2026

SCHEDULE 13G

BlackRock, Inc. (Filed by)

Oct 27, 2026

Robinson Chandler (Reporting)

Oct 20, 2026

STARR CHRISTOPHER M (Reporting)

Oct 5, 2026

Cittadine Andrew (Reporting)

Oct 2, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 10, 2025

CORRESP

Form CORRESP - Correspondence

Sep 5, 2025

LETTER

Form UPLOAD - SEC-generated letter

Sep 4, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jul 25, 2025

CORRESP

Form CORRESP - Correspondence

Jul 22, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jul 16, 2025

Monopar Therapeutics Inc. MNPR · SEC Filings